6 results about "Injections pain" patented technology

Embodiments relate to an autoinjector for automatic subcutaneous or intramuscular injection of a drug, and provide an ergonomic structure for grip stability, rolling prevention, visibility, and pain relief when a user presses the autoinjector against the skin to operate same. The autoinjector according to embodiments comprises a housing which forms the exterior, wherein the housing includes a support part and a grip part that have different maximum outer widths in a cross section perpendicular to a central axis thereof, the grip part extends in the axial direction on a distal side of the support part, and the maximum outer width of the grip part is smaller than the maximum outer width of the support part, thus preventing slipping. In addition, the cross section of the grip part has a non-circular quadrilateral contour, thereby preventing rolling, the housing includes a proximal part and a distal part that have different transparencies, thereby providing visibility and psychological stability, and an activation member that comes into contact with the skin includes, in a proximal end surface thereof, a protruding shape for increasing local pressure, thereby relieving injection pain.

Provided are an anti-IL-5 antibody lyophilized formulation and a reconstituted formulation thereof. The anti-IL-5 antibody lyophilized formulation comprises an anti-IL-5 antibody, a histidine buffer, sucrose, and polysorbate 80. The anti-IL-5 antibody lyophilized formulation has excellent stability, has a lower osmotic pressure after reconstitution, reduces injection pain for patients, and is more suitable for clinical use.

The invention discloses a famotidine injection and a preparation method thereof, and belongs to the field of pharmaceutical preparations. Every 1 mL of the famotidine injection comprises 10 mg of famotidine, 60-90 mg of nicotinamide, 10-14 mg of histidine and 0.4-0.8 mg of EDTA-Na2, water for injection is added until the total volume is 1 mL, and the pH value is 5.5-6.5. The preparation method comprises the following steps: sequentially dissolving EDTA-Na2, histidine, nicotinamide and famotidine under the condition of nitrogen charging protection, fixing the volume, adjusting the pH value, filtering, charging nitrogen, and encapsulating. According to the invention, lactic acid in an original research prescription is replaced by histidine, vitamin C is replaced by a nicotinamide-histidine-EDTA-Na2 synergistic system, and a whole-process nitrogen protection process is combined, so that the problems of injection pain, oxidative degradation of a main drug and easy precipitation due to a narrow pH window existing in an original research product are solved, and the safety, stability and quality controllability of the product are remarkably improved.

Various embodiments of the present disclosure provide methods and apparatus for reducing pain associated with injection of certain drug formulations. An apparatus as described herein comprises a first chamber or section containing a pharmaceutical formulation comprising menotropin or a variant thereof, a second chamber or section comprising a diluent, and a combining mechanism configured to puncture one or more of the first chamber or the section chamber to combine the pharmaceutical formulation and the diluent prior to injection. A method as described herein comprises actuating a combining mechanism which combines a pharmaceutical formulation comprising menotropin or a variant thereof and a diluent, and actuating an administering means which administers the pharmaceutical formulation and the diluent to a patient.

The application discloses a low-stimulus and high-safety benzoyl aconine original base temperature-sensitive analgesic gel injection as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The injection takes benzoyl aconine original base as a core analgesic component, constructs a triple heart protection system of'sub-anesthetic dose lidocaine + ammonium glycyrrhizinate + magnesium sulfate', cooperates with a poloxamer 407 temperature-sensitive gel matrix, and is supplemented with a cosolvent and an antioxidant, has a pH value of 5.5-6.5, can be injected at room temperature, and is quickly gelled at body temperature to realize long-acting controlled release. The preparation has high analgesic intensity, no addiction, slight injection pain, controllable cardiotoxicity, and can maintain analgesia for more than 12 hours after single administration, is suitable for local targeted treatment of moderate and severe chronic pain, neuropathic pain and the like, and has significant clinical advantages and popularization value.